The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall sur...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2024-09, Vol.103 (9), p.3293-3301 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3301 |
|---|---|
| container_issue | 9 |
| container_start_page | 3293 |
| container_title | Annals of hematology |
| container_volume | 103 |
| creator | Wang, Zerong Jin, Xuelian Zeng, Jiajia Xiong, Zilin Chen, Xinchuan |
| description | Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety. |
| doi_str_mv | 10.1007/s00277-024-05703-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11358344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3097957443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-258c0f585cff9764a8828c330c56b5f41237ffa1ab5fc98cbd787215f7fa80373</originalsourceid><addsrcrecordid>eNp9kT1vHCEQhlGUKL44-QMpIqQ0bjbh82CryLLyaUtunBqxHPiwdmEDnCWX-eeeyzpO7MI0MPDMy8y8CL2l5AMlRH2shDClOsJER6QivKPP0IoKziDU4jlakZ73nYR1gF7VekUIZVqwl-iAa9ELKekK_b7YemzneYzOtpgTzgH_OD7FMW3jEFsuFY64ATT7ErtWbKrzaFNb6P1l3uyTtn6yLc85-hYdrs1P2PlxxI8zQi54uvFjDnEoucb6Gr0Idqz-zd1-iH5--Xxx8q07O__6_eT4rHOCrVvHpHYkSC1dCL1aC6s1045z4uR6kEFQxlUIlloIXK_dsFFaMSqDClYTrvgh-rTozrth8hvnE5Q2mrnEyZYbk200D19S3JrLfG0o5VJzIUDh6E6h5F87X5uZYt03aZPPu2pYv1YweaUYoO8foVd5VxL0ZzjpVS8V6AHFFsrBJGrx4b4aSszeYrNYbMBi88diQyHp3f993Kf89RQAvgAVntKlL__-fkL2FoRrtPQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097957443</pqid></control><display><type>article</type><title>The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wang, Zerong ; Jin, Xuelian ; Zeng, Jiajia ; Xiong, Zilin ; Chen, Xinchuan</creator><creatorcontrib>Wang, Zerong ; Jin, Xuelian ; Zeng, Jiajia ; Xiong, Zilin ; Chen, Xinchuan</creatorcontrib><description>Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.</description><identifier>ISSN: 0939-5555</identifier><identifier>ISSN: 1432-0584</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-024-05703-1</identifier><identifier>PMID: 38494551</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Allografts ; Alopecia ; Baldness ; Cytokines ; Dermatitis ; Graft versus host disease ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Inflammatory bowel disease ; Janus Kinase 1 - antagonists & inhibitors ; Janus Kinase 2 - antagonists & inhibitors ; Janus Kinase Inhibitors - therapeutic use ; Kinases ; Lymphocytes ; Medical prognosis ; Medicine ; Medicine & Public Health ; Mortality ; Mutation ; Nitriles - therapeutic use ; Oncology ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - therapy ; Psoriatic arthritis ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Quality of life ; Review ; Review Article ; Rheumatoid arthritis ; Stem cell transplantation ; Steroids ; Tumors</subject><ispartof>Annals of hematology, 2024-09, Vol.103 (9), p.3293-3301</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-258c0f585cff9764a8828c330c56b5f41237ffa1ab5fc98cbd787215f7fa80373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-024-05703-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-024-05703-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38494551$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Zerong</creatorcontrib><creatorcontrib>Jin, Xuelian</creatorcontrib><creatorcontrib>Zeng, Jiajia</creatorcontrib><creatorcontrib>Xiong, Zilin</creatorcontrib><creatorcontrib>Chen, Xinchuan</creatorcontrib><title>The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.</description><subject>Allografts</subject><subject>Alopecia</subject><subject>Baldness</subject><subject>Cytokines</subject><subject>Dermatitis</subject><subject>Graft versus host disease</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Janus Kinase 1 - antagonists & inhibitors</subject><subject>Janus Kinase 2 - antagonists & inhibitors</subject><subject>Janus Kinase Inhibitors - therapeutic use</subject><subject>Kinases</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Nitriles - therapeutic use</subject><subject>Oncology</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - therapy</subject><subject>Psoriatic arthritis</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Quality of life</subject><subject>Review</subject><subject>Review Article</subject><subject>Rheumatoid arthritis</subject><subject>Stem cell transplantation</subject><subject>Steroids</subject><subject>Tumors</subject><issn>0939-5555</issn><issn>1432-0584</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kT1vHCEQhlGUKL44-QMpIqQ0bjbh82CryLLyaUtunBqxHPiwdmEDnCWX-eeeyzpO7MI0MPDMy8y8CL2l5AMlRH2shDClOsJER6QivKPP0IoKziDU4jlakZ73nYR1gF7VekUIZVqwl-iAa9ELKekK_b7YemzneYzOtpgTzgH_OD7FMW3jEFsuFY64ATT7ErtWbKrzaFNb6P1l3uyTtn6yLc85-hYdrs1P2PlxxI8zQi54uvFjDnEoucb6Gr0Idqz-zd1-iH5--Xxx8q07O__6_eT4rHOCrVvHpHYkSC1dCL1aC6s1045z4uR6kEFQxlUIlloIXK_dsFFaMSqDClYTrvgh-rTozrth8hvnE5Q2mrnEyZYbk200D19S3JrLfG0o5VJzIUDh6E6h5F87X5uZYt03aZPPu2pYv1YweaUYoO8foVd5VxL0ZzjpVS8V6AHFFsrBJGrx4b4aSszeYrNYbMBi88diQyHp3f993Kf89RQAvgAVntKlL__-fkL2FoRrtPQ</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Wang, Zerong</creator><creator>Jin, Xuelian</creator><creator>Zeng, Jiajia</creator><creator>Xiong, Zilin</creator><creator>Chen, Xinchuan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240901</creationdate><title>The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis</title><author>Wang, Zerong ; Jin, Xuelian ; Zeng, Jiajia ; Xiong, Zilin ; Chen, Xinchuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-258c0f585cff9764a8828c330c56b5f41237ffa1ab5fc98cbd787215f7fa80373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Allografts</topic><topic>Alopecia</topic><topic>Baldness</topic><topic>Cytokines</topic><topic>Dermatitis</topic><topic>Graft versus host disease</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Janus Kinase 1 - antagonists & inhibitors</topic><topic>Janus Kinase 2 - antagonists & inhibitors</topic><topic>Janus Kinase Inhibitors - therapeutic use</topic><topic>Kinases</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Nitriles - therapeutic use</topic><topic>Oncology</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - therapy</topic><topic>Psoriatic arthritis</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Quality of life</topic><topic>Review</topic><topic>Review Article</topic><topic>Rheumatoid arthritis</topic><topic>Stem cell transplantation</topic><topic>Steroids</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Zerong</creatorcontrib><creatorcontrib>Jin, Xuelian</creatorcontrib><creatorcontrib>Zeng, Jiajia</creatorcontrib><creatorcontrib>Xiong, Zilin</creatorcontrib><creatorcontrib>Chen, Xinchuan</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Zerong</au><au>Jin, Xuelian</au><au>Zeng, Jiajia</au><au>Xiong, Zilin</au><au>Chen, Xinchuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>103</volume><issue>9</issue><spage>3293</spage><epage>3301</epage><pages>3293-3301</pages><issn>0939-5555</issn><issn>1432-0584</issn><eissn>1432-0584</eissn><abstract>Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38494551</pmid><doi>10.1007/s00277-024-05703-1</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2024-09, Vol.103 (9), p.3293-3301 |
| issn | 0939-5555 1432-0584 1432-0584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11358344 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Allografts Alopecia Baldness Cytokines Dermatitis Graft versus host disease Hematology Hematopoietic Stem Cell Transplantation Humans Inflammatory bowel disease Janus Kinase 1 - antagonists & inhibitors Janus Kinase 2 - antagonists & inhibitors Janus Kinase Inhibitors - therapeutic use Kinases Lymphocytes Medical prognosis Medicine Medicine & Public Health Mortality Mutation Nitriles - therapeutic use Oncology Primary Myelofibrosis - drug therapy Primary Myelofibrosis - therapy Psoriatic arthritis Pyrazoles - therapeutic use Pyrimidines - therapeutic use Quality of life Review Review Article Rheumatoid arthritis Stem cell transplantation Steroids Tumors |
| title | The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A40%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20application%20of%20JAK%20inhibitors%20in%20the%20peri-transplantation%20period%20of%20hematopoietic%20stem%20cell%20transplantation%20for%20myelofibrosis&rft.jtitle=Annals%20of%20hematology&rft.au=Wang,%20Zerong&rft.date=2024-09-01&rft.volume=103&rft.issue=9&rft.spage=3293&rft.epage=3301&rft.pages=3293-3301&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-024-05703-1&rft_dat=%3Cproquest_pubme%3E3097957443%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3097957443&rft_id=info:pmid/38494551&rfr_iscdi=true |